nach oben

Quality of Life Research

Erschienen in:

18.05.2020

Genetic polymorphisms and haplotypes of BRCA1 gene associated with quality of life and survival among patients with non-small-cell lung cancer

verfasst von: Tong Su, Hao Sun, Xiaofang Lu, Chen He, Lei Xiao, Jingwen He, Yang Yang, Yunxiang Tang

Erschienen in: Quality of Life Research | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Quality of life (QoL) and prognosis of lung cancer (LC) patients are poor. Previous studies focused less on the relationship between genetic factors and the QoL of LC patients. The current study is intended to explore the association of SNPs and haplotypes of BRCA1 and the QoL and survival of patients with LC.

Methods

QOL of 291 non-small-cell LC patients was measured by EORTC Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire‐Lung Cancer 13 (QLQ-LC13) before discharge. Three tag SNPs of the BRCA1 gene (rs1799966, rs3737559, rs8067269) were detected using an improved multiplex ligation detection reaction (iMLDR) technique. Haplotype analysis was conducted using the software Haploview 4.2. The patients’ survival was followed up every six months until March 2019.

Results

rs8067269 was associated with physical functioning (β = 7.97, p = 0.024) and diarrhea (Odds ratios (OR) 0.32, p = 0.042). rs1799966–rs3737559–rs8067269 haplotype was associated with several domains of QoL, including physical functioning (TCG vs. CCA: β = 6.21, p = 0.010), worse dyspnea (TCG vs. CTA: OR 2.05, p = 0.031) and peripheral neuropathy (TCG vs. CTA: OR 3.91, p = 0.030). BRCA1 rs1799966 CC genotype, rs8067269 AA genotype and CCA haplotype were associated with longer survival time of LC patients (p < 0.05).

Conclusion

SNPs and haplotypes of BRCA1 gene were associated with the QoL and survival of patients with LC. Patients with certain genotypes and haplotypes (i.e., rs8067269 AA genotype, or CCA haplotype) had better QoL and prognosis.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

She, J., Yang, P., Hong, Q., & Bai, C. (2013). Lung cancer in China: Challenges and interventions. Chest, 143(4), 1117–1126. https://doi.org/10.1378/chest.11-2948.CrossRefPubMed

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492.CrossRef

Guo, H., Chang, Z., Wu, J., & Li, W. (2019). Air pollution and lung cancer incidence in China: Who are faced with a greater effect? Environment International, 132, 105077–105077. https://doi.org/10.1016/j.envint.2019.105077.CrossRefPubMed

Mackillop, W. J. (2007). Killing time: The consequences of delays in radiotherapy. Radiotherapy and Oncology, 84(1), 1–4.CrossRefPubMed

Chinese Medical Association Thoracic Society Lung Cancer, G. (2013). The review and future directions of lung cancer prevention and treatment. Chinese Journal of Tuberculosis and Respiratory Disease, 36(2), 898–901.

Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Jr., Wu, Y.-L., et al. (2017). Lung cancer: Current therapies and new targeted treatments. The Lancet, 389(10066), 299–311. https://doi.org/10.1016/S0140-6736(16)30958-8.CrossRef

Reale, M. L., De Luca, E., Lombardi, P., Marandino, L., Zichi, C., Pignataro, D., et al. (2020). Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. Lung Cancer, 139, 47–54. https://doi.org/10.1016/j.lungcan.2019.10.022.CrossRefPubMed

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87–108. https://doi.org/10.3322/caac.21262.CrossRef

10.

Yang, P., Cheville, A. L., Wampfler, J. A., Garces, Y. I., Jatoi, A., Clark, M. M., et al. (2012). Quality of life and symptom burden among long-term lung cancer survivors. Journal of Thoracic Oncology, 7(1), 64–70. https://doi.org/10.1097/JTO.0b013e3182397b3e.CrossRefPubMedPubMedCentral

11.

Belani, C. P., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., et al. (2006). Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life: A randomized controlled trial. Lung Cancer, 53(2), 231–239.CrossRefPubMed

12.

European Medicines, A. (2014). Reflection paper on the use of patient reported outcome measure in oncology studies.

13.

Food, U. S., & Drug, A. (2009). Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims.

14.

Montazeri, A. (2009). Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health and Quality of Life Outcomes, 7, 102–102. https://doi.org/10.1186/1477-7525-7-102.CrossRefPubMedPubMedCentral

15.

Braun, D. P., Gupta, D., & Staren, E. D. (2011). Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer, 11, 353–353. https://doi.org/10.1186/1471-2407-11-353.CrossRefPubMedPubMedCentral

16.

Ediebah, D. E., Coens, C., Zikos, E., Quinten, C., Ringash, J., King, M. T., et al. (2014). Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. British Journal of Cancer, 110(10), 2427–2433. https://doi.org/10.1038/bjc.2014.208.CrossRefPubMedPubMedCentral

17.

Xu, C. Q., Liu, W., & Li, Y. W. (2013). Study of relationship between changes in quality of life scores and survival time in patients with non-small cell lung cancer. Chinese Journal of Clinical Pulmonology, 18(6), 1090–1093.

18.

Cheng, X., Zhou, D., & Lu, L. (2004). Factors affecting the quality of life in lung cancer patients measured by EORTC QLQ questionnaire. Chinese Journal of Lung Cancer, 7(3), 230–235.PubMed

19.

Qian, M., Liu, X., & Zou, H. (2011). The investigation of factors influencing the life quality of female lung cancer patients in Shanghai. Chinese Journal of Clinical Medical Engineering, 18(5), 791–795.

20.

Larsson, M., Ljung, L., & Johansson, B. B. (2012). Health-related quality of life in advanced non-small cell lung cancer: Correlates and comparisons to normative data. European Journal of Cancer Care (Engl), 21(5), 642–649. https://doi.org/10.1111/j.1365-2354.2012.01346.x.CrossRef

21.

Sprangers, M. A. G., Sloan, J. A., Barsevick, A., Chauhan, C., Dueck, A. C., Raat, H., et al. (2010). Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Quality of life research, 19(10), 1395–1403. https://doi.org/10.1007/s11136-010-9759-5.CrossRefPubMedPubMedCentral

22.

Sprangers, M. A. G., Thong, M. S. Y., Bartels, M., Barsevick, A., Ordoñana, J., Shi, Q., et al. (2014). Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Quality of Life Research, 23(7), 1997–2013. https://doi.org/10.1007/s11136-014-0656-1.CrossRefPubMedPubMedCentral

23.

Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65.CrossRefPubMed

24.

Rausch, S. M., Clark, M. M., Patten, C., Liu, H., Felten, S., Li, Y., et al. (2010). Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer, 116(17), 4103–4113.CrossRefPubMed

25.

Sloan, J. A., de Andrade, M., Decker, P., Wampfler, J., Oswold, C., Clark, M., et al. (2012). Genetic variations and patient-reported quality of life among patients with lung cancer. Journal of Clinical Oncology, 30(14), 1699–1704. https://doi.org/10.1200/JCO.2010.34.5629.CrossRefPubMedPubMedCentral

26.

Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998). BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science, 281(5379), 1009–1012. https://doi.org/10.1126/science.281.5379.1009.CrossRefPubMed

27.

Kennedy, R. D., Quinn, J. E., Johnston, P. G., & Harkin, D. P. (2002). BRCA1: Mechanisms of inactivation and implications for management of patients. The Lancet, 360(9338), 1007–1014. https://doi.org/10.1016/S0140-6736(02)11087-7.CrossRef

28.

Rosella, R., Cobo, M., Isla, D., Miguel Sanchez, J., Taron, M., Altavilla, G., et al. (2005). Applications of genomics in NSCLC. Lung Cancer, 50, S33–S40. https://doi.org/10.1016/S0169-5002(05)81571-5.CrossRef

29.

Simon, G. R., Ismail-Khan, R., & Bepler, G. (2007). Nuclear excision repair-based personalized therapy for non-small cell lung cancer: From hypothesis to reality. The International Journal of Biochemistry & Cell Biology, 39(7), 1318–1328. https://doi.org/10.1016/j.biocel.2007.05.006.CrossRef

30.

Du, Y., Su, T., Zhao, L., Tan, X., Chang, W., Zhang, H., et al. (2014). Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS ONE, 9(6), e99843–e99843. https://doi.org/10.1371/journal.pone.0099843.CrossRefPubMedPubMedCentral

31.

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. JNCI, 85(5), 365–376. https://doi.org/10.1093/jnci/85.5.365.CrossRefPubMed

32.

Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. European Journal of Cancer, 30(5), 635–642.CrossRef

33.

Scott, N. W., Fayers, P., Aaronson, N. K., Bottomley, A., de Graeff, A., Groenvold, M., et al. (2008). EORTC QLQ-C30 reference values manual. Brussels: Quality of Life Department.

34.

Thomas, G., Sinville, R., Sutton, S., Farquar, H., Hammer, R. P., Soper, S. A., et al. (2004). Capillary and microelectrophoretic separations of ligase detection reaction products produced from low-abundant point mutations in genomic DNA. Electrophoresis, 25, 1668–1677.CrossRefPubMed

35.

Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004). Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21(2), 263–265. https://doi.org/10.1093/bioinformatics/bth457.CrossRefPubMed

36.

Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., et al. (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics, 81(3), 559–575. https://doi.org/10.1086/519795.CrossRefPubMedPubMedCentral

37.

Johnson, C., Pankratz, V. S., Velazquez, A. I., Aakre, J. A., Loprinzi, C. L., Staff, N. P., et al. (2015). Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. Journal of the Neurological Sciences, 349(1), 124–128. https://doi.org/10.1016/j.jns.2014.12.041.CrossRefPubMedPubMedCentral

38.

Alexander, K., Conley, Y. P., Levine, J. D., Cooper, B. A., Paul, S. M., Mastick, J., et al. (2018). Cytokine gene polymorphisms associated with various domains of quality of life in women with breast cancer. Journal of Pain and Symptom Management, 55(2), 334–350.e333. https://doi.org/10.1016/j.jpainsymman.2017.09.020.CrossRefPubMed

39.

Kim, H.-T., Lee, J.-E., Shin, E.-S., Yoo, Y.-K., Cho, J.-H., Yun, M.-H., et al. (2008). Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. Journal of Clinical Oncology, 26(36), 5972–5979. https://doi.org/10.1200/JCO.2008.16.6496.CrossRefPubMed

40.

Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M. S., et al. (2004). BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Human Molecular Genetics, 13(20), 2443–2449. https://doi.org/10.1093/hmg/ddh260.CrossRefPubMed

41.

Lee, S. Y., Kang, H.-G., Yoo, S. S., Kang, Y. R., Choi, Y. Y., Lee, W. K., et al. (2013). Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer, 82(2), 330–339. https://doi.org/10.1016/j.lungcan.2013.07.024.CrossRefPubMed

Titel: Genetic polymorphisms and haplotypes of BRCA1 gene associated with quality of life and survival among patients with non-small-cell lung cancer
verfasst von: Tong Su
Hao Sun
Xiaofang Lu
Chen He
Lei Xiao
Jingwen He
Yang Yang
Yunxiang Tang
Publikationsdatum: 18.05.2020
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 10/2020
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-020-02509-2

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

Clinical target achievement is associated with better quality of life among dialysis patients: results from a continuous quality improvement program in a Portuguese healthcare network

Health-related quality of life of type 2 diabetes patients hospitalized for a diabetes-related complication

The association of stroke severity with health-related quality of life in survivors of acute cerebrovascular disease and their informal caregivers during the first year post stroke: a survey study

Correction to: Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure

Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients

Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings